MAPT (Tau) expression is a biomarker for an increased rate of survival for low‑grade glioma

Zaman,Saif; Chobrutskiy,Boris I.; Sikaria,Dhiraj; Blanck,George

doi:10.3892/or.2018.6896

MAPT (Tau) expression is a biomarker for an increased rate of survival for low‑grade glioma

Authors:
- Saif Zaman
- Boris I. Chobrutskiy
- Dhiraj Sikaria
- George Blanck
View Affiliations

Affiliations: Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA
Published online on: November 28, 2018 https://doi.org/10.3892/or.2018.6896
Pages: 1359-1366

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The association of MAPT (Tau) with various tauopathies and other neurological disorders has long been established. However, the role of microtubule‑associated protein Tau (MAPT) expression in brain cancer is largely unknown. To determine whether MAPT expression is related to low‑grade glioma (LGG) survival rates, RNASeq data representing samples from the Cancer Genome Atlas (TCGA) were assessed. Results revealed that high expression of the MAPT gene is very strongly associated with increased overall and disease‑free survival in LGG but not in breast cancer or melanoma. No such association was apparent for either amyloid precursor protein or α‑synuclein gene expression. The expression levels of particular apoptosis‑ and pro‑proliferative‑effector genes were consistent with the Tau‑associated increased survival rates. It has been well established that the Tau protein plays a neurodegenerative role, and in this study we identified, for the first time, a potential cell apoptosis function that Tau may play in cancers of the central nervous system.

View Figures

View References

1	Spillantini MG and Goedert M: Tau pathology and neurodegeneration. Lancet Neurol. 12:609–622. 2013. View Article : Google Scholar : PubMed/NCBI
2	Ikeda K, Akiyama H, Arai T and Nishimura T: Glial tau pathology in neurodegenerative diseases: Their nature and comparison with neuronal tangles. Neurobiol Aging. 19 Suppl:S85–S91. 1998. View Article : Google Scholar : PubMed/NCBI
3	Hartmann C, Hentschel B, Tatagiba M, Schramm J, Schnell O, Seidel C, Stein R, Reifenberger G, Pietsch T, von Deimling A, et al: Molecular markers in low-grade gliomas: predictive or prognostic? Clin Cancer Res. 17:4588–4599. 2011. View Article : Google Scholar : PubMed/NCBI
4	Claus EB, Walsh KM, Wiencke JK, Molinaro AM, Wiemels JL, Schildkraut JM, Bondy ML, Berger M, Jenkins R and Wrensch M: Survival and low-grade glioma: The emergence of genetic information. Neurosurg Focus. 38:E62015. View Article : Google Scholar : PubMed/NCBI
5	Colodner KJ and Feany MB: Glial fibrillary tangles and JAK/STAT-mediated glial and neuronal cell death in a Drosophila model of glial tauopathy. J Neurosci. 30:16102–16113. 2010. View Article : Google Scholar : PubMed/NCBI
6	Li ZH, Xiong QY, Tu JH, Gong Y, Qiu W, Zhang HQ, Wei WS, Hou YF and Cui WQ: Tau proteins expressions in advanced breast cancer and its significance in taxane-containing neoadjuvant chemotherapy. Med Oncol. 30:5912013. View Article : Google Scholar : PubMed/NCBI
7	Koo DH, Lee HJ, Ahn JH, Yoon DH, Kim SB, Gong G, Son BH, Ahn SH and Jung KH: Tau and PTEN status as predictive markers for response to trastuzumab and paclitaxel in patients with HER2-positive breast cancer. Tumour Biol. 36:5865–5871. 2015. View Article : Google Scholar : PubMed/NCBI
8	Wang K, Deng QT, Liao N, Zhang GC, Liu YH, Xu FP, Zu J, Li XR and Wu YL: Tau expression correlated with breast cancer sensitivity to taxanes-based neoadjuvant chemotherapy. Tumour Biol. 34:33–38. 2013. View Article : Google Scholar : PubMed/NCBI
9	Zhou J, Qian S, Li H, He W, Tan X, Zhang Q, Han G, Chen G and Luo R: Predictive value of microtubule-associated protein Tau in patients with recurrent and metastatic breast cancer treated with taxane-containing palliative chemotherapy. Tumour Biol. 36:3941–3947. 2015. View Article : Google Scholar : PubMed/NCBI
10	Grossman RL, Heath AP, Ferretti V, Varmus HE, Lowy DR, Kibbe WA and Staudt LM: Toward a shared vision for cancer cenomic data. N Engl J Med. 375:1109–1112. 2016. View Article : Google Scholar : PubMed/NCBI
11	Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al: Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 6:pl12013. View Article : Google Scholar : PubMed/NCBI
12	Ping Z, Siegal GP, Almeida JS, Schnitt SJ and Shen D: Mining genome sequencing data to identify the genomic features linked to breast cancer histopathology. J Pathol Inform. 5:32014. View Article : Google Scholar : PubMed/NCBI
13	Mauro JA and Blanck G: Functionally distinct gene classes as bigger or smaller transcription factor traps: A possible stochastic component to sequential gene expression programs in cancer. Gene. 536:398–406. 2014. View Article : Google Scholar : PubMed/NCBI
14	Frost B, Götz J and Feany MB: Connecting the dots between tau dysfunction and neurodegeneration. Trends Cell Biol. 25:46–53. 2015. View Article : Google Scholar : PubMed/NCBI
15	Iijima-Ando K, Zhao L, Gatt A, Shenton C and Iijima K: A DNA damage-activated checkpoint kinase phosphorylates tau and enhances tau-induced neurodegeneration. Hum Mol Genet. 19:1930–1938. 2010. View Article : Google Scholar : PubMed/NCBI
16	Khurana V, Merlo P, DuBoff B, Fulga TA, Sharp KA, Campbell SD, Götz J and Feany MB: A neuroprotective role for the DNA damage checkpoint in tauopathy. Aging Cell. 11:360–362. 2012. View Article : Google Scholar : PubMed/NCBI
17	Kruman II, Wersto RP, Cardozo-Pelaez F, Smilenov L, Chan SL, Chrest FJ, Emokpae R Jr, Gorospe M and Mattson MP: Cell cycle activation linked to neuronal cell death initiated by DNA damage. Neuron. 41:549–561. 2004. View Article : Google Scholar : PubMed/NCBI
18	Silva AR, Santos AC, Farfel JM, Grinberg LT, Ferretti RE, Campos AH, Cunha IW, Begnami MD, Rocha RM, Carraro DM, et al: Repair of oxidative DNA damage, cell-cycle regulation and neuronal death may influence the clinical manifestation of Alzheimer's disease. PLoS One. 9:e998972014. View Article : Google Scholar : PubMed/NCBI
19	Simpson JE, Ince PG, Matthews FE, Shaw PJ, Heath PR, Brayne C, Garwood C, Higginbottom A and Wharton SB: Function MRCC; MRC Cognitive Function and Ageing Neuropathology Study Group: A neuronal DNA damage response is detected at the earliest stages of Alzheimer's neuropathology and correlates with cognitive impairment in the Medical Research Council's Cognitive Function and Ageing Study ageing brain cohort. Neuropathol Appl Neurobiol. 41:483–496. 2015. View Article : Google Scholar : PubMed/NCBI
20	Nishimura M, Tomimoto H, Suenaga T, Namba Y, Ikeda K, Akiguchi I and Kimura J: Immunocytochemical characterization of glial fibrillary tangles in Alzheimer's disease brain. Am J Pathol. 146:1052–1058. 1995.PubMed/NCBI
21	Ferrer I, López-González I, Carmona M, Arregui L, Dalfó E, Torrejón-Escribano B, Diehl R and Kovacs GG: Glial and neuronal tau pathology in tauopathies: Characterization of disease-specific phenotypes and tau pathology progression. J Neuropathol Exp Neurol. 73:81–97. 2014. View Article : Google Scholar : PubMed/NCBI
22	Arai T, Ikeda K, Akiyama H, Shikamoto Y, Tsuchiya K, Yagishita S, Beach T, Rogers J, Schwab C and McGeer PL: Distinct isoforms of tau aggregated in neurons and glial cells in brains of patients with Pick's disease, corticobasal degeneration and progressive supranuclear palsy. Acta Neuropathol. 101:167–173. 2001.PubMed/NCBI
23	Harada A, Oguchi K, Okabe S, Kuno J, Terada S, Ohshima T, Sato-Yoshitake R, Takei Y, Noda T and Hirokawa N: Altered microtubule organization in small-calibre axons of mice lacking tau protein. Nature. 369:488–491. 1994. View Article : Google Scholar : PubMed/NCBI
24	Mandelkow E and Mandelkow EM: Microtubules and microtubule-associated proteins. Curr Opin Cell Biol. 7:72–81. 1995. View Article : Google Scholar : PubMed/NCBI